A DNA-based vaccine containing human immunodeficiency virus type 1 (HIV-1) env and rev genes was tested for safety and host immune response in 15 asymptomatic HIV-infected patients who were not using antiviral drugs and who had CD4
Since its identification in 1981, the global AIDS epidemic
While no single measure of immunity is predictive of in vivo control of viral replication, there is mounting evidence has progressed inexorably to the point at which the cumulative total of human immunodeficiency virus (HIV) infections worldthat an efficacious therapeutic vaccine against HIV-1 will need to induce both cellular and humoral immune responses to conwide as of December 1996 was estimated by the Joint United Nations Programme on HIV/AIDS to be 29.4 million people, trol infection. Patients mounting strong gp160-specific cytotoxic T lymphocyte (CTL) responses have shown a rapid reducwith 22.6 million currently living with the infection [1] . Since the introduction of zidovudine in 1987, significant strides have tion of acute viremia and antigenemia, and a high level of CTL activity has been associated with long-term survival [8, 9] . In been made, using combinations of antiviral agents, in controlling the rate of HIV replication and immune deterioration in contrast, primary viremia and antigenemia were poorly controlled in patients in whom virus-specific CTL activity was infected persons; however, the costs are great and the treatments are only partially effective. Thus, there is great interest low or undetectable. High levels of antibodies, most notably neutralizing and cross-reactive neutralizing antibodies, have in vaccines that might augment a host's immune response to HIV so that viral proliferation and immune damage is slowed also been observed in the sera of long-term survivors [8] and in mothers who do not transmit HIV-1 to their babies [10 -or stopped [2 -7] . It is also hoped that any immune response 13]. More recently, it has been determined that a higher level to a therapeutic vaccine strong enough to control established of in vitro proliferation to p24 is associated with long-term infection would also be effective in preventing initial infection nonprogression and in vivo control of viral replication [14] . In in HIV-naive subjects.
general, stronger and broader immune responses have been associated with delayed disease progression and are likely to have a positive impact on limiting replication, although the genes that encode the env and rev proteins of HIV.
(2) quantitative HIV RNA polymerase chain reaction (PCR) of plasma, which was separated from cells and frozen at 070ЊC until shipped on dry ice for assay at LabCorp, Clinical Trials Testing Services (Research Triangle Park, NC). (3) antibodies against HIV env, measured by ELISA done with Study design. Sequential groups of 5 subjects received 3 intramodifications of previously described methods [10] . Briefly, remuscular injections of vaccine at the same dose [30, 100, or 300 combinant gp120 based on the MN sequence (Immunodiagnostics, mg) at 10-week intervals. The group of subjects to receive the next Bedford, MA) was resuspended in 11 PBS to a concentration of escalation of dose did not begin until 2 weeks after all 5 persons 0.5 mg/mL, and 50-mL volumes (25 ng) were incubated overnight in the previous dose level had received their first dose without at 4ЊC in 96-well plates. Next, plates were rinsed and incubated complication. The toxic dose that would trigger study discontinuawith blocking buffer for 2 h at 37ЊC. Serial serum dilutions were tion was defined as the lowest dose at which 2 of the 5 dosethen incubated in triplicate wells for 1 h at 37ЊC, washed, and cohort patients experienced any treatment-related adverse effect reincubated for 1 h with a goat anti-human immunoglobulin greater than or equal to grade 3 (World Health Organization crite-(Sigma, St. Louis). After being washed, the plates were colorria) or the dose at which a second adverse effect of the same type developed and read at 450 nm. Two human HIV-1-seronegative occurred.
Materials and Methods
sera were used as sample controls, and BSA-coated wells were The vaccine was administered in the Clinical Research Center used as negative binding controls. (CRC) of the Hospital of the University of Pennsylvania. An intra-(4) lymphoproliferative responses to mitogens and to HIV and venous catheter was inserted into each subject's arm before each tetanus toxoid antigens as determined using the method (described injection, and constant monitoring of clinical state and vital signs below) of Wang et al. [26] . Briefly, peripheral blood mononuclear was carried out for 2 h after administration of the vaccine. If stable, cells (PBMC) were separated by use of ficoll-hypaque. The PBMC the subject was then allowed to leave the CRC. A brief follow-up were then resuspended to a concentration of 1 1 10 6 /mL, and 100-visit occurred 24 h later, and subjects returned for monitoring visits mL aliquots were added to 96-well U-bottom microtiter plates. 1, 2, 4, 6, and 10 weeks later. If no adverse experiences were HIV gp120 baculovirus-produced protein (100 mL; Intracel, Issanoted at 10 weeks, the second dose was administered, and the quah, WA) was added to the wells in triplicate to final concentrasame 10-week cycle was repeated until the third dose at 20 weeks.
tions of 5.0, 0.5, and 0.05 mg/mL. The cells were incubated at Thereafter, the monitoring cycle was repeated a third time, and a 37ЊC in a CO 2 incubator for 3 days, and then 1 mCi of tritiated final monitoring visit occurred 36 weeks after the first inoculation.
thymidine (DuPont NEN, Wilmington, DE) was added to each In addition to the monitoring visits, patients kept a symptom log well and incubated overnight (12-18 h). Plates were harvested on which was reviewed at each visit. Data from the monitoring visits an automatic 96-well harvester, and the amount of incorporated were shared with the subjects as the study proceeded, and subjects tritiated thymidine measured in a microbeta counter. The stimulawere reminded that they were free to withdraw from participation tion index (SI) was calculated by dividing the counts per minute at any time.
(cpm) from cells exposed to specific stimulation by the cpm from Inclusion and exclusion criteria. Inclusion criteria required a cells incubated in media alone. To assure that cells were healthy, positive serum HIV ELISA antibody test confirmed by Western the nonspecific mitogen phytohemagglutinin (5 mg/mL) was added blot analysis, CD4
/ lymphocyte count §500/mL of blood, normal as a positive control to 3 wells. An increased response following serum chemistries and complete blood cell count (CBC), liver immunization was defined as a rise in SI of §4 above the preimmuenzymes £1.5 times the upper limits of normal, and, for women, nization value. Other baculovirus-derived HIV proteins were ina negative pregnancy test and commitment to the use of effective cluded in the assays as controls and consistently failed to induce birth control for the duration of the study.
responses. Exclusion criteria included prior receipt of any HIV vaccine, (5) CTL activity against vaccinia-infected autologous Epsteinantiretroviral therapy within the preceding 3 months, presence of Barr virus-transformed B cell lines expressing gp160. Blood was HIV-related symptoms, evidence of active hepatitis B or C infecdelivered to the laboratory within 30 min of phlebotomy, and tion or of antinuclear antibodies, history of an immunosuppressive PBMC were isolated by standard ficoll-hypaque separation, disease (other than HIV) or medication, allergy to amide-type local washed three times with PBS, and frozen in liquid nitrogen until anesthetics, or any acute or chronic debilitating illness unrelated the time of assay. At that time, they were resuspended in RPMI to HIV infection.
containing 10% fetal calf serum, 20 U/mL interleukin-2, and 5 Monitoring studies. Standard laboratory tests included CBC; mg/mL phytohemagglutinin. The PBMC were cultured for Ç3 urinalysis; serum levels of creatinine, liver enzymes, creatine kiweeks and then used in the CTL assay [29] . After 3 weeks' stimulation with media containing interleukin-2, the expanded T cells nase, and antinuclear antibodies; and erythrocyte sedimentation were §85% CD8 / as determined by flow cytometry. Background tory, Rockville, MD). These targets were washed once with serumfree medium, labeled for 2 h at room temperature with 50 mCi of NOTE. Lymphocyte counts were determined by flow cytometry.
51 Cr (DuPont NEN), washed three times with serum-free medium, * Eight subjects had levels £6000 copies/mL; 1 subject had undetectable and diluted with effector cells at target-to-effector cell ratios of levels (õ400 copies/mL).
1:12, 1:25, 1:50, and 1:100 in 96-well microtiter plates. To determine the spontaneous and maximum chromium release with cell lysis, three wells containing only targets were mixed with 100 mL multiple washes and ending with a resuspension of the RNA into of media or Triton X-100, respectively. After the effector and the Amplicor sample diluent. The lower limit of detection for target cells were incubated at 37ЊC in 5% CO 2 for 5 h, 100 mL of the assay was 400 copies/mL, and assay variability for the same supernatant was removed, and the amount of 51 Cr release was specimen from day to day ranged up to 50% (Lawrence Corey, measured in a gamma counter. Specific CTL release was calculated personal communication). Similar variability has been reported by as 100 1 [(experimental release 0 spontaneous release)/(maxiothers [34, 35] . mum release 0 spontaneous release)]. An increased response following immunization was defined as a rise of §10 percentage points above the preimmunization percentage value at one or more 
2-week intervals; 60% of repeat determinations varied by
The plasmid is formulated with bupivacaine (an amide type anes-õ20%, but the remainder had second values as much as 57% thetic), which enhances in vivo transfection, gene expression, and higher or lower than the first, a well-known phenomenon in immune responses as previously described [31] . The study was subjects with high CD4 cell counts. Mean preimmunization remained within normal range in most subjects and increased associated with a transient rise of §0.5 log, and 4 were followed by a transient fall of §0.5 log. by ú50% above the upper limit of normal in 3: Bilirubin increased to 1.7 mg/dL in 1 subject, and alanine aminotransferFlow cytometry results. Figure 2 shows the CD4 and CD8 ase and aspartate aminotransferase increased to 2.5 times the values for each subject at the time of study entry and again at upper limit of normal in 2 subjects. All levels returned to 36 weeks. As with plasma HIV, no clear pattern is evident. normal during the study.
Because of inherent variability in these values in the same subject from day to day, we arbitrarily chose to regard a change The erythrocyte sedimentation rate increased to 32, 37, 55, and 57 in 1 subject each but returned to normal during the of ú20% from baseline as potentially significant. CD4 cell counts increased by §20% in 3 subjects (CD4 cell percents study. Creatine kinase increased to twice the normal upper limit in 2 subjects and returned to normal limits while they increased in 3) and CD4 cell counts decreased by §20% in 5 subjects (percents decreased by §20% in only 1 subject). The received subsequent doses. Two subjects had random glucose determinations between 110 -150 mg% on 5 occasions. One mean CD4 cell count for the group was 764/mL on entry and 692/mL at week 36 (compared with an average of an 80-cell subject had persistent mild proteinuria (trace amounts to 100 mg) throughout the study. Of note, no subject developed abnorloss/year in some natural-history studies). CD8 lymphocyte counts increased by §20% in 1 subject (CD8 cell percent mal vital signs following injection, no significant increases in antinuclear antibodies titer were observed, and anti-DNA increased in none) and fell by §20% in 4 (percent decreased in only 1). The mean CD8 cell count for the group on entry antibody was not detected.
was 1199/mL, and it was 1094 at week 36. Plasma HIV RNA PCR copies. Figure 1 shows the plasma RNA PCR values for each subject at the time of study entry Antibody responses. Table 2 shows the preimmunization geometric mean antibody levels against Env gene product for and again at 36 weeks (16 weeks after the third injection). No clear pattern of rising or falling copy number is evident. Beeach subject (average of specimens obtained 2 weeks before and the day of the first injection) soon after completing the cause differences of up to 0.5 logs can be seen due to assay variability [29] , we collated changes in excess of that magniprimary series of injections (week 21 -24) and at week 36 (16 weeks after the third and last immunizing injection to determine tude: 2 subjects experienced a rise in plasma copy number of §0.5 log (from 2.32 to 2.90 and from 3.86 to 4.75); no subject the durability of any changes noted). Values for the 30-mg cohort demonstrated essentially no increase in geometric mean experienced a decrease of §0.5 log, although 1 declined from 4.19 to 3.72 logs. We also looked for transient changes immedititer (GMT). Persons in the 100-and 300-mg cohorts showed increases of more than twice baseline level at weeks 21 or 36 ately after each injection: 7 of the 45 total injections were / 9d4a$$jy41 05-18-98 12:07:32 jinfa UC: J Infect (or both). Thus, there appeared to be a threshold dose of vaccine after vaccination. The relationship between vaccination and the rises in individual patient's CTL activity is uncertain. above which an antibody response could be anticipated.
CTL responses. Because we were not able to immortalize Lymphocyte proliferative responses. Specimen availability allowed for assay of lymphoproliferative responses directed against lymphocytes from all participants, specimen availability permitted assay in 10 of the 15 vaccine recipients for specific CTL HIV antigen and against phytohemagglutinin for cells from 3 subjects at each dose level. Table 4 shows responses (expressed responses against HIV-1 gp160 -expressing targets. Table 3 shows the CTL activity for subjects in each dose cohort, exas SI) to gp120 of preimmunization lymphocytes and of lymphocytes 21 and 36 weeks after the first dose. Increased proliferative pressed as percent specific lysis, at the same monitoring times as sampled for antibody above. No increase in CTL activity was responses (SI §4 above baseline) were noted at all vaccine concentrations, without a clear dose response. seen in the group that received 30-mg vaccine doses, whereas 2 of the 3 subjects in the 100-mg group showed increases of 10
Quantitative HIV RNA PCR of semen. Semen specimens from the 10 men who received the 100-and 300-mg vaccine percentage points or more in specific CTL. Perhaps related to high preimmunization CTL activity is the fact that none of the doses were tested. Five had levels of HIV RNA below the level of detection (õ400 copies/mL of plasma) before vaccination, 3 subjects in the 300-mg group had increased CTL activity / 9d4a$$jy41 05-18-98 12:07:32 jinfa UC: J Infect by proliferation of media alone. Phytohemagglutinin was used as positive control and to assess health of peripheral blood mononuclear cells. gp120 was NOTE. Titers were determined by using highest dilution of antisera with derived from HIV-1 IIIB . Preimmune data are averages for 2 preinoculation time optical density (OD) at 450 nm that was elevated compared with level of points. reactivity in normal human sera. End-point titers were determined by extrapo-* Week 11. lating to titer that was nearest to 3 SD above OD of normal human sera at its lowest dilution.
Determined at weeks *30, † 25, ‡ 26, and § 34.
and 5 had counts of 751, 790, 900, 957, and 7003 copies/mL. Specimens obtained during week 21, 1 week after the third Table 3 . Specific lysis of HIV-1 gp160-expressing targets at an immunization, from the 5 men who had detectable virus in effector-to-target cell ratio of 50:1 for 10 of 15 HIV-1 -infected subsemen before vaccination and 1 whose level was õ400 were jects vaccinated with various doses of a DNA-based vaccine containing HIV-1 env and rev genes.
assayed. Two specimens from the 5 men who originally had detectable HIV RNA had levels below the level of detection % specific lysis on week 21, and the other 3 men had counts 21%, 41%, and ated with long-term survival [8, 9] . However, primary viremia galactose) was used to assess background lysis of vaccinia-infected cells. Sponand antigenemia were poorly controlled in patients in whom taneous release was £20% of maximum. * Spontaneous release Ç32% -43% of maximum.
virus-specific CTL activity was low or undetectable. Further-/ 9d4a$$jy41 05-18-98 12:07:32 jinfa UC: J Infect more, a definite CTL response has been observed in Gambian A secondary objective of the study was to monitor for changes in the course of the subjects' HIV infection, utilizing sex workers who remain seronegative as well as PCR-negative for HIV-1 despite repeated exposures [37, 38] . High levels of the surrogate markers of CD4 / lymphocyte counts and plasma HIV RNA PCR copies. The absolute numbers and percents of neutralizing and cross-reactive neutralizing antibodies have also been observed in the serum of long-term survivors [8] .
CD4 / and CD8 / lymphocytes varied but without obvious pattern. Some subjects demonstrated both a 20% increase and a Other conceptually related studies demonstrated that stronger serologic responses are present in mothers who do not transmit similar decrease at different times during the study. The plasma RNA PCR copy number has been reported by some investiga-HIV-1 to their babies [10 -13] .
Although this observation is controversial, stronger and tors to increase after receipt of other vaccines, such as influenza and tetanus, although study results have been mixed [43 -47] . broader immune responses have been associated with delayed disease progression, and are believed to limit viral replication, Numbers in our vaccine recipients failed to show a clear trend.
When values at the end of study (week 36) were compared although the ability of the immune response to affect viral replication in infected individuals remains unsubstantiated [39] .
with the patients' starting values, significant increases in virus load were only detected in 2 of 15 subjects. Transient increases Overall, it is thought that a useful goal for immune therapy of HIV would be to raise and broaden antigen-specific anti-HIV of §0.5 logs were noted after 7 of the 45 injections, whereas transient decreases of the same degree occurred after 4 injeccellular and humoral responses.
Recent efforts have demonstrated the safety and immunogetions. The absence of sustained increases in plasma virus load further supports the benign nature of this approach. On balance, nicity in humans of several recombinant protein products, including recombinant gp160 [2, 3] , LAI gp120 [4], and MN there was no clear trend to indicate that receiving the vaccine either was detrimental or beneficial to the course of the two gp120 [5] . In addition, there is some evidence to suggest that vaccination with recombinant envelope and vaccinia preparasurrogate markers of HIV infection. In addition, attempts to quantitate HIV RNA in semen by PCR in 10 men revealed tions used as immunotherapy can expand anti -HIV-1 immune responses [6, 7, 39 -42] . Although these immunogens did not detectable virus in 5; however, after vaccination, the values were lower or undetectable in 4. If changes in virus load in affect HIV virus load, some impact was noted on antiviral cellular and humoral immune responses. Accordingly, examithis compartment were observed in an adequately powered study, they could indicate a potential use for such a vaccine to nation of an immunogen that can induce cellular immunity is important for developing immune therapy for HIV.
reduce HIV transmission. Our other secondary objective was to determine whether DNA vaccines represent a novel application of gene therapy, which has as one of its strengths the ability to induce a cellular administration of an HIV DNA vaccine to subjects already infected with the virus would or would not induce changes immune response. Specifically in the case of HIV, both immunotherapeutic as well prophylactic applications of DNA vacin measurable immune responses. Both antibody-and cellmediated immune responses were studied. We compared anticines have shown the ability to impact viral replication in animal models [18, 23 -27] .
body GMTs against gp120 as well as specific CTL responses and T lymphocyte proliferation from the subjects measured at DNA vaccines have not been evaluated previously in humans. The primary objective of this study was to determine three times: immediately before initiating the 3-dose series of injections, immediately after the third dose (week 21), and 4 the safety of an HIV DNA vaccine in HIV-infected subjects. We found that the intramuscular administration of vaccine conmonths later (week 36). Although the sample sizes were too small to make conclusions, there were interesting differences taining the env and rev genes of HIV, given as a series of 3 injections at 10-week intervals, using doses of 30, 100, or 300 observed based on dose group. For example, there was a lack of apparent boosting in antibody titers in the 30-mg dose group, mg, was safe (i.e., without significant clinical or laboratory complication) in 15 subjects. No local injection reactions were but subjects in the 100-and 300-mg groups displayed rises in GMTs by 36 weeks. Examination of CTL responses showed observable, and the 4 subjective reports of local tenderness were mild and not recurrent. Subjects experiencing nausea adthat 0 of 4 patients in the 30-mg group had a §10 percentage point increase in their CTL level compared with prevaccination mitted to being anxious about receiving their injection. One subject's observation of a ''scratchy throat'' was coincident levels. However, 2 of the 3 patients in the 100-mg group had an increase of §10 percentage points in CTL responses at one with an upper respiratory infection. Liver chemistry elevations were mild, and one episode was related to an acute attack of or more time points during follow-up. The lack of an increase in CTL activity in the 300-mg group may have resulted from hepatitis A in the subject. Sedimentation rates rose transiently in 4 subjects and returned to normal while the subjects rehigh levels of activity present before vaccination in 2 of 3 subjects. However, the inherent variability of the CTL assay mained in the study. Of note, the subjects lacked antinuclear antibody formation, muscle enzyme elevation, and changes in makes it unwise to draw any firm conclusion and indicates that further studies will be required to resolve this issue. Lymphoblood pressure and pulse. Thus, the short-term negative effects of the vaccine were negligible, and no participant withdrew cyte proliferative responses did not show a dose-dependent response: The SI increased by §4 in 2 of 3 patients in the 30-because of adverse effects.
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